CompletedNot Applicable

Myoglobin Removal With CytoSorb in Rhabdomyolysis

Turkey (Türkiye)17 participantsStarted 2024-08-01

Plain-language summary

The aim of this observational study is to assess whether myoglobin removal with CytoSorb® ameliorates endothelial damage in severe rhabdomyolysis patients who are admitted to the intensive care unit. The primary objective of the study is: \- Does myoglobin removal with CytoSorb® reduces glycocalyx degradation markers? Patients with severe rhabdomyolysis will receive the intervention and blood samples will be obtained in regular intervals.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with Creatine Kinase \> 5000 IU/L. * Myoglobin results can be obtained only after 5 working days after sampling in our center, therefore it cannot be used as an inclusion criteria. * GFR below 40 ml/min. Exclusion Criteria: * High dose vasopressor requirement * Not expected to survive \> 24 h * Lack of consent to participate

What they're measuring

Syndecan-1

Timeframe: 12 hour

Trial details

NCT IDNCT06503289

SponsorSisli Hamidiye Etfal Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-22

View on ClinicalTrials.gov More Acute Kidney Injury trials